X. Jin

发表

A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer

Keda Yu, G. Di, Z. Shao, 2016, BMC Cancer.

A Nomogram for Predicting the Pathological Response of Axillary Lymph Node Metastasis in Breast Cancer Patients

G. Di, Z. Shao, Yizhou Jiang, 2016, Scientific Reports.

Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin

Z. Shao, Sheng Chen, Ruo-Xi Wang, 2016, Scientific Reports.

Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy.

Z. Shao, Da-Qiang Li, Wei Huang, 2022, Cell metabolism.

The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation

Xin Hu, Xiao-En Xu, Keda Yu, 2019, Science Advances.

The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer.

Xin Hu, Z. Shao, Da-Qiang Li, 2022, Cell metabolism.

Transcriptome analysis of luminal breast cancer reveals a role for LOL in tumor progression and tamoxifen resistance

Xiao-En Xu, Z. Shao, Xianghuo He, 2019, International journal of cancer.

Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value.

Xin Hu, Xin Hu, Xiao-En Xu, 2016, Cancer research.

Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer

Xin Hu, Xiao-En Xu, Keda Yu, 2016, Breast Cancer Research.

Proteome-centric cross-omics characterization and integrated network analyses of triple-negative breast cancer.

Z. Shao, Da-Qiang Li, Peng-Yuan Yang, 2022, Cell reports.

Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer

Z. Shao, Yi Xiao, Yizhou Jiang, 2019, Theranostics.

The early-stage triple-negative breast cancer landscape derives a novel prognostic signature and therapeutic target

Xiao-En Xu, Z. Shao, Yizhou Jiang, 2021, Breast Cancer Research and Treatment.

Transcriptome Analysis Derives a Novel Prognostic 7-mRNA Signature in Early-Stage Triple-Negative Breast Cancer

Xiao-En Xu, Z. Shao, Yizhou Jiang, 2021 .

LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer

Xiao-En Xu, G. Di, Da-Qiang Li, 2020, Molecular Cancer.

PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer

Xin Hu, Z. Shao, B. Lian, 2021, Cancer Research.

Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer

Xiao-En Xu, Keda Yu, Z. Shao, 2018, Theranostics.

Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor

G. Di, Z. Shao, Yizhou Jiang, 2021, Oncogene.

DSCAM‐AS1 regulates the G1/S cell cycle transition and is an independent prognostic factor of poor survival in luminal breast cancer patients treated with endocrine therapy

Xiao-En Xu, Z. Shao, Yirong Liu, 2018, Cancer medicine.

MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer

Xin Hu, Xiao-En Xu, Z. Shao, 2021, Journal for ImmunoTherapy of Cancer.

Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study

Keda Yu, G. Di, Z. Shao, 2015, Oncotarget.

Integrated molecular profiling of young and elderly patients with triple‐negative breast cancer indicates different biological bases and clinical management strategies

Xiao-En Xu, Z. Shao, Yi Xiao, 2020, Cancer.

High expression of TLR3 in triple-negative breast cancer predicts better prognosis—data from the Fudan University Shanghai Cancer Center cohort and tissue microarrays

L. Fan, Z. Shao, Wenjin Zhang, 2023, BMC Cancer.

GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer

Xin Hu, Xiao-En Xu, Z. Shao, 2021, Journal for ImmunoTherapy of Cancer.

Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis

Z. Shao, Can-ming Chen, Sheng Chen, 2016, Breast Cancer Research and Treatment.

Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.

Z. Shao, Yizhou Jiang, Y. Gong, 2019, Breast.

Superenhancer drives a tumor-specific splicing variant of MARCO to promote triple-negative breast cancer progression

Z. Shao, G. Di, Shenglin Huang, 2022, Proceedings of the National Academy of Sciences of the United States of America.

CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer.

Z. Shao, Li Chen, Yizhou Jiang, 2023, Med.

Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer

Xin Hu, Xiao-En Xu, Keda Yu, 2016, Breast Cancer Research.

Luminal B subtype: A key factor for the worse prognosis of young breast cancer patients in China

G. Di, Z. Shao, L. Tang, 2015, BMC Cancer.

Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer

Z. Shao, G. Di, Yizhou Jiang, 2021, Journal for ImmunoTherapy of Cancer.

A Novel Seven Gene Signature-Based Prognostic Model to Predict Distant Metastasis of Lymph Node-Negative Triple-Negative Breast Cancer

G. Di, Z. Shao, Guan-Hua Su, 2021, Frontiers in Oncology.

Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations

L. Fan, Keda Yu, Guangyu Liu, 2020, Breast Cancer Research and Treatment.

Calcifications in triple-negative breast cancer: Molecular features and treatment strategies

Z. Shao, G. Di, X. Jin, 2023, NPJ breast cancer.

Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer

Z. Shao, Yizhou Jiang, D. Ma, 2023, Nature communications.

Molecular classification of hormone receptor-positive HER2-negative breast cancer

Wei Huang, Yizhou Jiang, D. Ma, 2023, Nature Genetics.

ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer

Tian-Jian Yu, D. Ma, Shen Zhao, 2024, Cell research.